Prodrugs have emerged as a transformative strategy in modern drug development, enabling the optimization of pharmacokinetics, targeted delivery, and therapeutic efficacy across a wide range of disease areas. By temporarily modifying active pharmaceutical ingredients, prodrug approaches can overcome key limitations such as poor solubility, low bioavailability, systemic toxicity, and lack of selectivity. With growing advances in medicinal chemistry, enzymology, nanotechnology, and computational design, prodrugs are increasingly being engineered for precision activation in specific tissues or pathological environments, making them highly relevant in oncology, infectious diseases, neurological disorders, and beyond.

Despite these advances, several challenges remain. These include incomplete understanding of bioconversion mechanisms, variability in enzymatic activation across patient populations, difficulties in predicting in vivo performance, regulatory complexities, and translational gaps between preclinical success and clinical outcomes. Additionally, the design of stimuli-responsive and targeted prodrugs requires improved integration of multidisciplinary knowledge and robust validation strategies.

This Collection aims to provide a comprehensive platform that captures recent progress in prodrug science, spanning (but not limited to) rational design strategies, novel chemical linkers, enzyme-activated systems, nanocarrier-associated prodrugs, and disease-specific applications. It will feature high-quality research articles, insightful reviews, and methodological advancements that address both fundamental principles and translational innovations.

By bringing together diverse contributions from academia and industry, this collection will serve as a valuable resource for researchers seeking to design next-generation therapeutics. It will foster interdisciplinary collaboration, highlight emerging trends, and accelerate the development of safer, more effective, and clinically translatable prodrug systems.